<?xml version="1.0" encoding="UTF-8"?>
<p id="Par52">There are several novel approaches, being tested in laboratories and clinical research for their ability to target RV-induced infection. These include soluble ICAM-1 receptor interfering with RV attachment (tremacamra), and two anti-viral drugs (pleconaril and ruprintrivir) as well as the application of inhaled IFN-Î² after the onset of a respiratory tract viral infection in asthmatic subjects. All of them, however, show only marginal benefit in symptoms, viral replication, and development of clinical symptoms of colds, while exhibiting substantial side effects [
 <xref ref-type="bibr" rid="CR71">71</xref>].
</p>
